LabHealth
Low-dose THC holds breast cancer cells in tumor models
The four-day treatment used organoids grown from mouse tumors and patient samples.
Written by AI1 source1 min
Loading…
Diagnostics, prosthetics, vaccines, genomics: the medicine that adds years to a life.
Medicine that wins years of life: AI-assisted screening examining millions of patients, next-generation vaccines, genomics moving from sequencing to treatment, prosthetics and implants restoring lost abilities. The section follows completed clinical trials, market authorisations, hospital roll-outs — the moment a technology stops being a paper and becomes care.
The numbers rule: cohorts, detection rates, avoided mortality, costs. We gladly cover the health systems deploying at scale — India, Brazil, Southeast Asia — because frugal technologies often prove themselves there before arriving anywhere else. Every article rests on the trial, authorisation or study behind it, and cites them.
The four-day treatment used organoids grown from mouse tumors and patient samples.
Antisense RNA delivered with nanoparticles blocked Smyca's activity in tumors and improved responses to existing treatments.
Breast cancer survivors recalled fewer story details despite matching controls on word-pair memory tests.
The University of Michigan team turned a gut-bacteria metabolite into an oral nano-delivered prodrug.
Kumamoto researchers analyzed DNA packaging, not just mutations, in blood samples from breast cancer cases.
Columbia researchers linked engineered human bone and lung tissues by vascular flow on one chip.
The ASPIRE phase 1/2 trial tested four targeted drugs in 29 previously untreated patients.
Risca's team tracked liposarcoma and ER-positive breast cancer cells for nearly a month.
The molecules reduced lung, breast cancer and melanoma cell viability in laboratory tests.
The work remains preclinical, using human cells, organoids and laboratory models.